Abstract
Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab beta induces robust expansion of the $CD56^{bright}$ subpopulation of NK cells that is correlated with the drug’s therapeutic effects. As NK cells represent a heterogeneous population of lymphocytes with a range of phenotypes and functions, the goal of this study was to better understand how daclizumab beta altered the NK cell repertoire to provide further insight into the possible mechanism(s) of action in RMS. We used mass cytometry to evaluate expression patterns of NK cell markers and provide a comprehensive assessment of the NK cell repertoire in individuals with RMS treated with daclizumab beta or placebo over the course of one year. Treatment with daclizumab beta significantly altered the NK cell repertoire compared to placebo treatment. As previously reported, daclizumab beta significantly increased expression of CD56 on total NK cells. Within the $CD56^{bright}$ NK cells, treatment was associated with multiple phenotypic changes, including increased expression of NKG2A and NKp44, and diminished expression of CD244, CD57, and NKp46. While the changes were less dramatic, $CD56^{dim}$ NK cells responded distinctly to daclizumab beta treatment, with higher expression of CD2 and NKG2A, and lower expression of FAS-L, HLA-DR, NTB-A, NKp30, and Perforin. Together, these data indicate that the expanded NK cells share features of both immature and mature NK cells. These findings show that daclizumab beta treatment is associated with unique changes in NK cells that may enhance their ability to kill autoreactive T cells or to exert immunomodulatory functions.
Introduction
Multiple Sclerosis (MS) is a chronic autoimmune disorder characterized by the immune system's attack on the central nervous system, primarily driven by autoreactive T cells. Daclizumab beta, a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, was developed to treat relapsing forms of MS (RMS). While its clinical efficacy was linked to the expansion of $CD56^{bright}$ Natural Killer (NK) cells, the specific phenotypic and functional changes within these cells remained poorly understood.
NK cells are traditionally categorized into two subsets: the "immature" $CD56^{bright}$ cells, known for cytokine production, and the "mature" $CD56^{dim}$ cells, which possess potent cytotoxic capabilities. This study, published by Ranganath et al., utilizes high-dimensional mass cytometry to determine whether the expansion induced by daclizumab beta represents a simple increase in immature cells or a fundamental transformation into a unique functional state.
Methods
To analyze the complex immune landscape, the researchers employed Mass Cytometry (CyTOF). Unlike traditional flow cytometry, CyTOF uses heavy metal isotopes to label cellular markers, allowing for the simultaneous measurement of over 40 markers without spectral overlap.
Data Analysis
The high-dimensional data was processed using two primary computational tools:
- CytoGLMM: A generalized linear mixed model framework designed to identify protein markers that predict treatment status (drug vs. placebo) while controlling for inter-patient variability.
- UMAP (Uniform Manifold Approximation and Projection): A dimensionality reduction technique used to visualize the distribution and density of cell populations in a 2D map.
Cohorts
The study analyzed cryopreserved peripheral blood mononuclear cells (PBMCs) from the SELECT and DECIDE clinical trials. The dataset included 30 individuals treated with daclizumab beta and 17 placebo controls, with samples collected at Baseline, Week 24, and Week 52. A reference cohort of 17 healthy donors was also included.
Results
The Hybrid Phenotype
The most significant finding was the emergence of a "hybrid" phenotype within the $CD56^{bright}$ population. These cells maintained immature markers like NKG2A but began expressing markers typically associated with mature, cytotoxic NK cells, such as Perforin and CD16. This suggests that daclizumab beta drives $CD56^{bright}$ cells toward a state that combines high proliferative capacity with enhanced killing machinery.
Predictive Markers of Treatment
Using CytoGLMM, the researchers identified specific markers that distinguished treated patients from controls. In $CD56^{bright}$ cells, treatment was strongly associated with:
- Increased expression: NKG2A, NKp44, and CD2.
- Decreased expression: CD244 (2B4), CD57, and NKp46.
Interestingly, the $CD56^{dim}$ population—usually the primary cytotoxic subset—showed a decrease in several activation and killing markers, including FAS-L and Perforin. This suggests a functional shift where the expanded $CD56^{bright}$ population may take over regulatory or cytotoxic roles usually held by other subsets.
Stability and Visualization
UMAP visualizations confirmed that drug-treated cells occupied a distinct density space compared to placebo cells. These phenotypic shifts were not transient; they were established by Week 24 and remained stable through the one-year study period, indicating a sustained remodeling of the NK cell repertoire.
Discussion
The findings suggest that daclizumab beta does not merely increase the quantity of NK cells but "educates" them. The increased expression of inhibitory receptors like NKG2A and KIR2DL3 may fine-tune the cells' ability to distinguish between healthy tissue and the autoreactive T cells responsible for MS pathology. By shifting $CD56^{bright}$ cells toward a more cytotoxic profile (increased Perforin), the drug may enhance the immune system's ability to eliminate rogue T cells.
Limitations and Conclusion
While this study provides a high-resolution map of NK cell changes, several questions remain. The analysis was limited to circulating blood, leaving it unclear if these hybrid NK cells successfully migrate to MS lesions in the central nervous system. Furthermore, the study is phenotypic; functional "killing assays" are needed to confirm the cytotoxic efficiency of these cells against T cells.
Finally, it is important to note that daclizumab beta was withdrawn from the market in 2018 due to rare inflammatory brain side effects. Future research must determine if the unique NK cell transformations identified here are purely therapeutic or if they play a role in the drug's adverse events. Nevertheless, this study highlights the power of mass cytometry in decoding the complex mechanisms of immunomodulatory therapies.
Summary updated